Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Compare

1,246 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDGL Analyst Ratings

Strong Buy

11 Buy

1 Hold

1 Sell

Based on 13 analysts giving stock ratings to

Madrigal

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDGL Stock 12 Month Forecast

Average Price Target

$427.91

▲(54.12%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $427.91 with a high forecast of $540.00 and a low forecast of $248.00. The average price target represents a 54.12% change from the last price of $277.64.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"208":"$208","541":"$541","291.25":"$291.3","374.5":"$374.5","457.75":"$457.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":540,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$540.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":427.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$427.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":248,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$248.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[208,291.25,374.5,457.75,541],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,272.67,293.2338461538462,313.79769230769233,334.3615384615385,354.92538461538464,375.4892307692308,396.0530769230769,416.61692307692306,437.1807692307692,457.7446153846154,478.30846153846153,498.8723076923077,519.4361538461538,{"y":540,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,272.67,284.6115384615385,296.55307692307696,308.4946153846154,320.43615384615384,332.3776923076923,344.3192307692308,356.26076923076926,368.2023076923077,380.1438461538462,392.08538461538467,404.02692307692314,415.96846153846155,{"y":427.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,272.67,270.7723076923077,268.8746153846154,266.9769230769231,265.0792307692308,263.1815384615385,261.2838461538462,259.38615384615383,257.48846153846154,255.59076923076924,253.69307692307692,251.79538461538462,249.8976923076923,{"y":248,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":210.59,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":236.16,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.31,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":334.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":323.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.67,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$540.00

Average Price Target$427.91

Lowest Price Target$248.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas SmithLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/20/25

Madrigal Pharmaceuticals: Positive CHMP Opinion and Phase 3 Success Drive Buy Rating

Andrea NewkirkGoldman Sachs

Goldman Sachs

$540

Buy

94.50%

Upside

Reiterated

06/20/25

Positive CHMP Opinion Boosts Madrigal Pharmaceuticals' Prospects for Rezdiffra in EU Market

Jonathan WollebenCitizens JMP

Citizens JMP

$470

Buy

69.28%

Upside

Reiterated

06/05/25

Citizens JMP Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

Edward NashCanaccord Genuity

Canaccord Genuity

$420

Buy

51.28%

Upside

Reiterated

05/13/25

Promising Phase III Trial Results Support Buy Rating for Madrigal Pharmaceuticals

Jason ZemanskyBank of America Securities

Bank of America Securities

$248

Sell

-10.68%

Downside

Reiterated

05/13/25

Uncertainties and Data Gaps Lead to Sell Rating for Madrigal Pharmaceuticals' Rezdiffra

David LebowitzCiti

Citi

$469→$456

Buy

64.24%

Upside

Reiterated

05/13/25

Citi reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)Citi analyst David Lebowitz reiterated a Buy rating and $456.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)

Ritu BaralTD Cowen

TD Cowen

$390

Buy

40.47%

Upside

Reiterated

05/12/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Liisa BaykoEvercore ISI

Evercore ISI

$392

Buy

41.19%

Upside

Reiterated

05/02/25

Evercore ISI Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

Eliana MerleUBS

UBS

$441→$458

Buy

64.96%

Upside

Reiterated

05/02/25

Madrigal Pharmaceuticals price target raised to $458 from $441 at UBSMadrigal Pharmaceuticals price target raised to $458 from $441 at UBS

Mayank MamtaniB.Riley Financial

B.Riley Financial

$422→$460

Buy

65.68%

Upside

Reiterated

05/02/25

Analysts Are Bullish on These Healthcare Stocks: Cerus (CERS), Madrigal Pharmaceuticals (MDGL)

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Hold

―

Reiterated

04/29/25

Cantor Fitzgerald reiterates Neutral Rating on Madrigal Pharmaceuticals (MDGL)Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).

Jay OlsonOppenheimer

Oppenheimer

$475

Buy

71.08%

Upside

Reiterated

04/27/25

Madrigal Pharmaceuticals' Rezdiffra: A Promising First-Mover in MASH Treatment with Strong Growth Potential

Akash TewariJefferies

Jefferies

$398

Buy

43.35%

Upside

Reiterated

04/22/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ed ArceH.C. Wainwright

H.C. Wainwright

$400→$405

Buy

45.87%

Upside

Reiterated

02/27/25

Madrigal price target raised to $405 from $400 at H.C. WainwrightMadrigal price target raised to $405 from $400 at H.C. Wainwright

Yasmeen RahimiPiper Sandler

Piper Sandler

$336→$400

Buy

44.07%

Upside

Reiterated

02/14/25

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas SmithLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/20/25

Madrigal Pharmaceuticals: Positive CHMP Opinion and Phase 3 Success Drive Buy Rating

Andrea NewkirkGoldman Sachs

Goldman Sachs

$540

Buy

94.50%

Upside

Reiterated

06/20/25

Positive CHMP Opinion Boosts Madrigal Pharmaceuticals' Prospects for Rezdiffra in EU Market

Jonathan WollebenCitizens JMP

Citizens JMP

$470

Buy

69.28%

Upside

Reiterated

06/05/25

Citizens JMP Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

Edward NashCanaccord Genuity

Canaccord Genuity

$420

Buy

51.28%

Upside

Reiterated

05/13/25

Promising Phase III Trial Results Support Buy Rating for Madrigal Pharmaceuticals

Jason ZemanskyBank of America Securities

Bank of America Securities

$248

Sell

-10.68%

Downside

Reiterated

05/13/25

Uncertainties and Data Gaps Lead to Sell Rating for Madrigal Pharmaceuticals' Rezdiffra

David LebowitzCiti

Citi

$469→$456

Buy

64.24%

Upside

Reiterated

05/13/25

Citi reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)Citi analyst David Lebowitz reiterated a Buy rating and $456.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)

Ritu BaralTD Cowen

TD Cowen

$390

Buy

40.47%

Upside

Reiterated

05/12/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Liisa BaykoEvercore ISI

Evercore ISI

$392

Buy

41.19%

Upside

Reiterated

05/02/25

Evercore ISI Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

Eliana MerleUBS

UBS

$441→$458

Buy

64.96%

Upside

Reiterated

05/02/25

Madrigal Pharmaceuticals price target raised to $458 from $441 at UBSMadrigal Pharmaceuticals price target raised to $458 from $441 at UBS

Mayank MamtaniB.Riley Financial

B.Riley Financial

$422→$460

Buy

65.68%

Upside

Reiterated

05/02/25

Analysts Are Bullish on These Healthcare Stocks: Cerus (CERS), Madrigal Pharmaceuticals (MDGL)

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Hold

―

Reiterated

04/29/25

Cantor Fitzgerald reiterates Neutral Rating on Madrigal Pharmaceuticals (MDGL)Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).

Jay OlsonOppenheimer

Oppenheimer

$475

Buy

71.08%

Upside

Reiterated

04/27/25

Madrigal Pharmaceuticals' Rezdiffra: A Promising First-Mover in MASH Treatment with Strong Growth Potential

Akash TewariJefferies

Jefferies

$398

Buy

43.35%

Upside

Reiterated

04/22/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ed ArceH.C. Wainwright

H.C. Wainwright

$400→$405

Buy

45.87%

Upside

Reiterated

02/27/25

Madrigal price target raised to $405 from $400 at H.C. WainwrightMadrigal price target raised to $405 from $400 at H.C. Wainwright

Yasmeen RahimiPiper Sandler

Piper Sandler

$336→$400

Buy

44.07%

Upside

Reiterated

02/14/25

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

1 Month

xxx

Success Rate

13/23 ratings generated profit

Average Return

+8.64%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +8.64% per trade.

3 Months

xxx

Success Rate

14/23 ratings generated profit

Average Return

+16.98%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +16.98% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

24/36 ratings generated profit

Average Return

+56.32%

reiterated a buy rating 22 days ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +56.32% per trade.

2 Years

xxx

Success Rate

31/36 ratings generated profit

Average Return

+81.73%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.11% of your transactions generating a profit, with an average return of +81.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDGL Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDGL has received 17 Buy Ratings, 1 Hold Ratings, and 3 Sell Ratings. MDGL average Analyst price target in the past 3 months is 427.91.

Each month's total comprises the sum of three months' worth of ratings.

MDGL Financial Forecast

MDGL Earnings Forecast

Next quarter’s earnings estimate for MDGL is -$3.49 with a range of -$5.15 to -$1.99. The previous quarter’s EPS was -$3.32. MDGL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year MDGL has Outperformed its overall industry.

MDGL Sales Forecast

Next quarter’s sales forecast for MDGL is $156.24M with a range of $128.00M to $174.50M. The previous quarter’s sales results were $137.25M. MDGL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year MDGL has Outperformed its overall industry.

MDGL Stock Forecast FAQ

What is MDGL’s average 12-month price target, according to analysts?

Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is 427.91.

What is MDGL’s upside potential, based on the analysts’ average price target?

Madrigal Pharmaceuticals Inc has 54.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDGL a Buy, Sell or Hold?

Madrigal Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 1 sell ratings.

What is Madrigal Pharmaceuticals Inc’s price target?

The average price target for Madrigal Pharmaceuticals Inc is 427.91. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $540.00 ,the lowest forecast is $248.00. The average price target represents 54.12% Increase from the current price of $277.64.

What do analysts say about Madrigal Pharmaceuticals Inc?

Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of MDGL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

MDGL Analyst Ratings

MDGL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Madrigal Pharmaceuticals

MDGL Analyst Recommendation Trends

MDGL Financial Forecast

MDGL Earnings Forecast

MDGL Sales Forecast

MDGL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts